Michaela Dvořáková

Postdoctoral researcher in neuroscience/cannabinoids at IU Bloomington.
2016/2017 @czechfulbright

[Neuroscience News @NeuroscienceNew]

Tylenol Targets Pain Through Unexpected Endocannabinoid Pathway

New research reveals that acetaminophen (Tylenol) reduces pain by lowering levels of the endocannabinoid 2-AG, contradicting the long-held belief that endocannabinoid activation relieves pain.

The drug works by inhibiting an enzyme that produces 2-AG, which usually activates CB1 receptors—the same ones involved in cannabis’s effects.

Surprisingly, the study found that reducing 2-AG actually led to less pain, suggesting a more complex role for this molecule in the body.

This discovery offers a potential new target for designing safer pain medications that avoid acetaminophen’s known liver toxicity.

With over 60 million Americans using acetaminophen weekly, understanding its mechanism is critical for future drug development.

The team now plans to investigate whether drugs like ibuprofen and aspirin act through similar pathways.

[Michaela Dvořáková @DSE_chaser]

We recently published a study highlighting a novel mechanism of coincidence detection that involves the interaction between cannabinoid and muscarinic receptors @PharmacolRes.
Read more:
https://t.co/wSAS9r3FQD

[Michaela Dvořáková @DSE_chaser]

Publishing negative data should not be impossible.
https://t.co/wLeZ0Om0Ez

[Michaela Dvořáková @DSE_chaser]

May the 4th be with you.
Do you also name your lab equipment?